Endocrine Abstracts

This study investigated risk of cardiovascular (CV) events over a period of up to 5 years in adult patients with chronic hypoparathyroidism treated with recombinant human parathyroid hormone (1–84), rhPTH(1–84), compared with a historical control cohort of patients who did not receive rhPTH(1––84). The rhPTH(1–84)-treated patient cohort was derived from the NCT00732615 (REPLACE), NCT01...

Background: Prior small studies have suggested increased risk of cardiovascular (CV) conditions in patients with hypoparathyroidism (HypoPT). We evaluated whether chronic HypoPT is associated with increased risk of select CV hard endpoints (i.e., myocardial infarction (MI), stroke, and a composite CV endpoint) in a large contemporary cohort.Methods: A retrospective cohort study, based on a US commercial claims database (Q1 2007 - Q2 2017), was conducted ...